Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Konoplev

Showing results (241-250 of 259) with videos related to

Pageof 26
Sort By:
Oncotarget|November 3, 2016
Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypesPolina Matre, Juliana Velez, Rodrigo Jacamo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2015
Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia ModelsJuliana Benito, Marc S Ramirez, Niki Zacharias Millward, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|February 26, 2019
Developing Innovative, Robust and Affordable Medical Linear Accelerators for Challenging EnvironmentsM Dosanjh, A Aggarwal, D Pistenmaa, et al.
The American Journal of Surgical Pathology|February 13, 2016
Prognostic Factors of Hepatosplenic T-cell Lymphoma: Clinicopathologic Study of 28 CasesMariko Yabe, L Jeffrey Medeiros, Guilin Tang, et al.
Journal of Medicinal Chemistry|December 7, 2007
Design and synthesis of human immunodeficiency virus entry inhibitors: sulfonamide as an isostere for the alpha-ketoamide groupRong-Jian Lu, John A Tucker, Tatiana Zinevitch, et al.
Haematologica|February 16, 2015
Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemiaMarina Konopleva, Peter F Thall, Cecilia Arana Yi, et al.
Research Square|May 10, 2023
Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesisKatie H Hurrish, Yongwei Su, Shraddha Patel, et al.
Journal of Medicinal Chemistry|June 19, 2009
Heterobiaryl human immunodeficiency virus entry inhibitorsRong-Jian Lu, John A Tucker, Jason Pickens, et al.
Blood|December 7, 2016
Ph-like acute lymphoblastic leukemia: a high-risk subtype in adultsNitin Jain, Kathryn G Roberts, Elias Jabbour, et al.
Biochemical Pharmacology|December 11, 2023
Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis in vitroKatie H Hurrish, Yongwei Su, Shraddha Patel, et al.
Pageof 26

Showing results (241-250 of 259) with videos related to

Sort By:
Pageof 26
Oncotarget|November 3, 2016
Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypesPolina Matre, Juliana Velez, Rodrigo Jacamo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 2015
Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia ModelsJuliana Benito, Marc S Ramirez, Niki Zacharias Millward, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|February 26, 2019
Developing Innovative, Robust and Affordable Medical Linear Accelerators for Challenging EnvironmentsM Dosanjh, A Aggarwal, D Pistenmaa, et al.
The American Journal of Surgical Pathology|February 13, 2016
Prognostic Factors of Hepatosplenic T-cell Lymphoma: Clinicopathologic Study of 28 CasesMariko Yabe, L Jeffrey Medeiros, Guilin Tang, et al.
Journal of Medicinal Chemistry|December 7, 2007
Design and synthesis of human immunodeficiency virus entry inhibitors: sulfonamide as an isostere for the alpha-ketoamide groupRong-Jian Lu, John A Tucker, Tatiana Zinevitch, et al.
Haematologica|February 16, 2015
Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemiaMarina Konopleva, Peter F Thall, Cecilia Arana Yi, et al.
Research Square|May 10, 2023
Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesisKatie H Hurrish, Yongwei Su, Shraddha Patel, et al.
Journal of Medicinal Chemistry|June 19, 2009
Heterobiaryl human immunodeficiency virus entry inhibitorsRong-Jian Lu, John A Tucker, Jason Pickens, et al.
Blood|December 7, 2016
Ph-like acute lymphoblastic leukemia: a high-risk subtype in adultsNitin Jain, Kathryn G Roberts, Elias Jabbour, et al.
Biochemical Pharmacology|December 11, 2023
Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis in vitroKatie H Hurrish, Yongwei Su, Shraddha Patel, et al.
Pageof 26